146 related articles for article (PubMed ID: 29599381)
1. Secondary mania following cancer chemotherapy with capecitabine.
Garg H; Prakash S; Deb KS; Chadda RK
BMJ Case Rep; 2018 Mar; 2018():. PubMed ID: 29599381
[TBL] [Abstract][Full Text] [Related]
2. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
Pandor A; Eggington S; Paisley S; Tappenden P; Sutcliffe P
Health Technol Assess; 2006 Nov; 10(41):iii-iv, xi-xiv, 1-185. PubMed ID: 17049138
[TBL] [Abstract][Full Text] [Related]
3. Acute reversible toxic encephalopathy during capecitabine and oxaliplatin treatment.
Godinho J; Casa-Nova M; Mesquita T; Baptista MJ; Araújo F; Vale J; Passos Coelho JL
J Oncol Pharm Pract; 2019 Mar; 25(2):497-501. PubMed ID: 29121830
[TBL] [Abstract][Full Text] [Related]
4. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
[TBL] [Abstract][Full Text] [Related]
5. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
Schmoll HJ; Twelves C; Sun W; O'Connell MJ; Cartwright T; McKenna E; Saif M; Lee S; Yothers G; Haller D
Lancet Oncol; 2014 Dec; 15(13):1481-1492. PubMed ID: 25456367
[TBL] [Abstract][Full Text] [Related]
6. A Case of Capecitabine-induced Hyperammonemia in a Patient with Colon Cancer.
Fang W; Fu Y; Wei J
Curr Drug Saf; 2018; 13(1):55-58. PubMed ID: 28782476
[TBL] [Abstract][Full Text] [Related]
7. Severe disabling sensory-motor polyneuropathy during oxaliplatin-based chemotherapy.
Leonard GD; Wagner MR; Quinn MG; Grem JL
Anticancer Drugs; 2004 Aug; 15(7):733-5. PubMed ID: 15269607
[TBL] [Abstract][Full Text] [Related]
8. Renal tubular acidosis secondary to capecitabine, oxaliplatin, and cetuximab treatment in a patient with metastatic colon carcinoma: a case report and review of the literature.
Sonnenblick A; Meirovitz A
Int J Clin Oncol; 2010 Aug; 15(4):420-2. PubMed ID: 20217448
[TBL] [Abstract][Full Text] [Related]
9. Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. The MetaPan study.
Leone F; Artale S; Marino D; Cagnazzo C; Cascinu S; Pinto C; Fornarini G; Tampellini M; Di Fabio F; Sartore-Bianchi A; De Carlis L; Pugliese R; Capussotti L; Gioeni L; Siena S; Aglietta M
Cancer; 2013 Oct; 119(19):3429-35. PubMed ID: 23868516
[TBL] [Abstract][Full Text] [Related]
10. Oxaliplatin-induced posterior reversible encephalopathy syndrome (PRES).
Janjua TK; Hassan M; Afridi HK; Zahid NA
BMJ Case Rep; 2017 Oct; 2017():. PubMed ID: 28978604
[TBL] [Abstract][Full Text] [Related]
11. A Feasibility Study of Capecitabine and Oxaliplatin for Patients with Stage II/III Colon Cancer -ACTOR Study.
Suenaga M; Akiyoshi T; Shinozaki E; Fujimoto Y; Matsusaka S; Konishi T; Nagayama S; Fukunaga Y; Kawakami K; Yokokawa T; Sugisaki T; Ueno M; Yamaguchi T
Anticancer Res; 2018 Mar; 38(3):1741-1747. PubMed ID: 29491111
[TBL] [Abstract][Full Text] [Related]
12. Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: A retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group.
Kwakman JJ; Simkens LH; Mol L; Kok WE; Koopman M; Punt CJ
Eur J Cancer; 2017 May; 76():93-99. PubMed ID: 28286287
[TBL] [Abstract][Full Text] [Related]
13. Utilization of capecitabine plus oxaliplatin and 5-fluorouracil/folinic acid plus oxaliplatin in the adjuvant treatment of stage IIB and stage III colon cancer: A multi-centre, retrospective, chart review study.
Sha A; Abadi S; Gill S
J Oncol Pharm Pract; 2018 Oct; 24(7):501-506. PubMed ID: 28714378
[TBL] [Abstract][Full Text] [Related]
14. Oxaliplatin and capecitabine chemotherapy for advanced colorectal cancer: a single institution's experience.
Sumpter K; Harper-Wynne C; Cunningham D; Gillbanks A; Norman AR; Hill M
Clin Oncol (R Coll Radiol); 2003 Aug; 15(5):221-6. PubMed ID: 12924449
[TBL] [Abstract][Full Text] [Related]
15. [Comparison of the efficacy and safety of capecitabine or tegafur, gimeracil and oteracil potassium capsules combined with oxaliplatin chemotherapy regimens in the treatment of advanced gastric cancer].
Wan Y; Hui H; Wang X; Wu J; Sun S
Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):28-34. PubMed ID: 26796803
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
[TBL] [Abstract][Full Text] [Related]
17. Unilateral Capecitabine-related Hand-foot Syndrome.
Matsuda S; Koketsu H; Hayakawa M; Nagata N
Intern Med; 2015; 54(21):2779. PubMed ID: 26521911
[No Abstract] [Full Text] [Related]
18. Toxicity Associated with Capecitabine in Patients Suffering from Dihydropyrimidine Dehydrogenase Deficiency.
Bermejo-Pérez MJ; Galeote-Miguel AM; Rodelo-Haad LE; Alés-Díaz I; Durán-Ogalla G; Benavides-Orgaz M
Chemotherapy; 2014; 60(5-6):353-5. PubMed ID: 26330092
[TBL] [Abstract][Full Text] [Related]
19. Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction.
Deenen MJ; Meulendijks D; Boot H; Legdeur MC; Beijnen JH; Schellens JH; Cats A
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1285-95. PubMed ID: 26499900
[TBL] [Abstract][Full Text] [Related]
20. Redefining adjuvant chemotherapy in patients with stage III colon cancer: X-ACT trial.
Glen H; Cassidy J
Expert Rev Anticancer Ther; 2008 Apr; 8(4):547-51. PubMed ID: 18402521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
